Description
Balchem: Inside The VitaCholine Breakthrough That Could Redefine Its Consumer Health Story!
Balchem Corporation reported strong financial results for the first quarter of 2026, demonstrating growth across its three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Consolidated revenue reached a record $271 million, marking an 8.1% year-over-year increase, driven partly by a 2% favorable foreign currency exchange impact due to a stronger euro. The company also delivered record adjusted EBITDA of $74 million, a 12.1% increase, and an adjusted net earnings of $43 million, up 7.4%, translating into adjusted diluted EPS of $1.33, a 9% rise. The Human Nutrition & Health segment, accounting for a majority of sales at $172 million, enjoyed an 8.3% increase supported by robust demand for minerals, nutrients, and food ingredients aligned with consumer preferences toward better-for-you, nutrient-dense products. This segment’s earnings rose 5.4%, partially offset by higher input costs and operating expenses.
